Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.

NCT04392479 is registered in ClinicalTrials.gov with Hôpital Franco-Britannique-Fondation Cognacq-Jay as lead sponsor.

NCT NCT04392479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04392479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.
Lead sponsor
Hôpital Franco-Britannique-Fondation Cognacq-Jay
Phase
Phase 3
Overall status
Unknown status
Start date
September 2, 2020
Completion date
June 30, 2024
Enrollment
202 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer colorectal, metastasis